ACADIA Pharmaceuticals Inc.
ACAD
$27.44
$0.893.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 278.63M | 264.57M | 244.32M | 259.60M | 250.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 278.63M | 264.57M | 244.32M | 259.60M | 250.40M |
| Cost of Revenue | 109.48M | 98.69M | 98.66M | 122.53M | 85.46M |
| Gross Profit | 169.16M | 165.88M | 145.66M | 137.07M | 164.94M |
| SG&A Expenses | 133.40M | 133.51M | 126.37M | 130.08M | 133.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 242.88M | 232.19M | 225.03M | 252.61M | 218.76M |
| Operating Income | 35.76M | 32.37M | 19.29M | 6.99M | 31.64M |
| Income Before Tax | 44.60M | 40.21M | 27.78M | 161.09M | 38.81M |
| Income Tax Expenses | -27.18M | 13.55M | 8.79M | 17.34M | 6.04M |
| Earnings from Continuing Operations | 71.78M | 26.67M | 18.99M | 143.74M | 32.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.78M | 26.67M | 18.99M | 143.74M | 32.77M |
| EBIT | 35.76M | 32.37M | 19.29M | 6.99M | 31.64M |
| EBITDA | 38.71M | 35.31M | 22.24M | 12.20M | 34.21M |
| EPS Basic | 0.43 | 0.16 | 0.11 | 0.86 | 0.20 |
| Normalized Basic EPS | 0.17 | 0.15 | 0.10 | 0.05 | 0.15 |
| EPS Diluted | 0.42 | 0.16 | 0.11 | 0.86 | 0.20 |
| Normalized Diluted EPS | 0.16 | 0.15 | 0.10 | 0.05 | 0.15 |
| Average Basic Shares Outstanding | 168.84M | 167.83M | 166.81M | 166.54M | 165.97M |
| Average Diluted Shares Outstanding | 170.65M | 168.68M | 167.67M | 166.70M | 166.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |